AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Secondary Data Analysis of Patients at Risk for CKD to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic Behaviour, Treatment Patterns and Patient Characteristics
Completed
- Conditions
- Chronic Kidney Diseases
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800211
- Registration Number
- NCT05953701
- Locations
- 🇩🇪
Research Site, Koblenz, Germany
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Phase 2
Recruiting
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT05952024
- Locations
- 🇵🇷
Research Site, San Juan, Puerto Rico
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
Phase 2
Active, not recruiting
- Conditions
- Mantle Cell Lymphoma (MCL)
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 108
- Registration Number
- NCT05951959
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3
Recruiting
- Conditions
- Breast Cancer, Early Breast Cancer
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5500
- Registration Number
- NCT05952557
- Locations
- 🇬🇧
Research Site, Whitchurch, United Kingdom
Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
Completed
- Conditions
- Muscle-invasive Bladder CancerNon Muscle Invasive Bladder CancerUrothelial Carcinoma
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT05945108
- Locations
- 🇧🇷
Research Site, Sao Paulo, Brazil
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
Phase 3
Active, not recruiting
- Conditions
- Non-Muscle- Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT05943106
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
Phase 2
Active, not recruiting
- Conditions
- Advanced or Metastatic NSCLC
- Interventions
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39
- Registration Number
- NCT05941897
- Locations
- 🇷🇺
Research Site, St. Petersburg, Russian Federation
A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA
Active, not recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 625
- Registration Number
- NCT05939128
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
Phase 1
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT05938270
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
Benralizumab Patient Access Programme Study: Retrospective Study in UK Severe Asthma Centres
Completed
- Conditions
- Asthma
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 276
- Registration Number
- NCT05932849
- Locations
- 🇬🇧
Addenbrookes Hospital, Cambridge, United Kingdom
🇬🇧St Bartholomew's Hospital, London, United Kingdom
🇬🇧St James's University Hospital, Leeds, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath